According to Nova One Advisor, the global exosome research market size is calculated at USD 225.72 million in 2025 and is expected to reach around USD 961.41 million by 2034, growing at a compound annual growth rate (CAGR) of 17.47% over the forecast period from 2025 to 2034.
Ottawa, Nov. 03, 2025 (GLOBE NEWSWIRE) — The global exosome research market size was valued at USD 192.15 billion in 2024 and is anticipated to reach around USD 961.41 million by 2034, growing at a compound annual growth rate (CAGR) of 17.47% over the forecast period from 2025 to 2034. A study published by Nova One Advisor a sister firm of Precedence Research.
Exosome research Market Report Highlights
- North America dominated the exosome research market with the revenue shares in 2024.
- Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
- By product type, the reagents and kits segment held the largest market share in 2024.
- By product type, the RNA/DNA extraction kits segment is expected to grow at the fastest CAGR in the market during the forecast period.
- By application, the cancer research segment led the market with the largest revenue share in 2024.
- By application, the drug delivery systems segment is expected to grow at the fastest CAGR in the market during the forecast period.
- By workflow, the isolation segment held the highest market share in 2024.
- By workflow, the microfluidics-based isolation segment is expected to grow at the fastest CAGR in the market during the forecast period.
- By end user, the academic & research institutes segment dominated the market in 2024.
- By end user, the pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR in the market during the forecast period.
Download a Sample Report Here@ https://www.novaoneadvisor.com/report/sample/9263
What is Exosome Research?
The global exosome research market is growing; its healthcare applications of exosomes include them as a biomarker, cell-free therapeutic agents, drug delivery transporters, basic investigation for exosome kinetics, and oncology vaccines. Exosomes are produced naturally in the human body and are not susceptible to immunogenicity, which would otherwise elicit a host response. Exosomes have garnered recent attention for their potential as a drug delivery vehicle, which enhances factors such as bioavailability of cargo load, adverse effect outlines, off-target effect, and pharmacokinetics for pharmaceutical molecules.
What are the Key Drivers in the Exosome Research Market?
Exosomes are nanovesicles representing an emerging field as a new means of information exchange across various research areas. They serve as a next-generation therapeutic platform and have diagnostic roles, acting as potential carriers to deliver therapies to cells because they are rich in cargos like proteins and nucleic acids. Exosomes are found in biological fluids such as plasma, serum, urine, and saliva. This review offers a comprehensive overview of exosome biogenesis, extraction methods, and their potential applications in diagnostics, therapy, and neurodegenerative disease detection. It also highlights their importance as valuable biomedical tools and their roles in drug delivery vehicles, contributing to the growth of the exosome research market.
For more information, visit the Nova One Advisor website or email the team at sales@novaoneadvisor.com | Call us : +1 804 420 9370
Report Scope of Exosome Research Market
| Report Attribute | Details |
| Market size value in 2025 | USD 225.72 million |
| Revenue forecast in 2033 | USD 961.41million |
| Growth rate | CAGR of 17.47% from 2025 to 2034 |
| Actual data | 2021 – 2024 |
| Forecast period | 2025 – 2034 |
| Quantitative units | Revenue in USD million and CAGR from 2025 to 2034 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | By Product Type, By Application, By Workflow, By End User, By Region |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait; Qatar; Oman |
| Key companies profiled | Thermo Fisher Scientific, Bio-Techne Corporation, System Biosciences (SBI), QIAGEN, NanoView Biosciences, Miltenyi Biotec, Danaher Corporation, Exosome Diagnostics, Lonza, Norgen Biotek Corp, Malvern Panalytical, NanoFCM, Creative Biolabs, AMS Biotechnology, Evox Therapeutics, HansaBioMed Life Sciences, Diagenode, Exosomics, Aruna Bio, Labcorp Drug Development |
| Customization scope | Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
What are the Ongoing Trends in the Exosome Research Market?
- In June 2025, Rion Aesthetics, an internationally recognized regenerative aesthetics company, announced that the U.S. Food and Drug Administration (FDA) had allowed an Investigational New Drug (IND) application to proceed for a Phase 1 investigator-initiated trial evaluating Purified Exosome Product injected into the dermis. The study is sponsored and independently conducted by Clinical Testing Center of Beverly Hills and is being led by Dr. John H. Joseph, a double board-certified facial plastic surgeon based in California.
- In April 2025, QIAGEN N.V. announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling. New QIAseq panels launched for use on next-generation sequencers to boost analysis of over 700 genes for comprehensive genomic profiling in research and clinical applications
- In July 2025, Exosome Diagnostics Inc., a leader in the liquid biopsy market, announced the close of its $30 million Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners. Blue Ridge Capital, NGN Capital, Arcus Ventures, b-to-v Partners, CD Ventures, and others participated in the round, which was oversubscribed.
What is the Emerging Challenge in the Exosome Research Market?
A requirement for greater initial spending in research, multifaceted and ineffective cell detachment technology, government obstacles, and the need for standardization and skilled labor are creating significant limitations in the overall exosome research market growth.
Regional Analysis
Why did North America Dominate the Market in 2024?
By capturing a major share, North America registered dominance in the market in 2024 a well-established medical care substructure, substantial R&D spending, the strong presence of key market players, and favorable government initiatives and reimbursement guidelines. North America is a hub of many healthcare organizations in the sequencing field, including Illumina, Thermo Fisher Scientific, and Agilent Technologies. Growing government initiative, for instance, in October 2025, GeneDx announced the first U.S. national genomic newborn screening initiative launched with $14.4 million NIH award.
How did the Asia Pacific Grow Notably in the Market in 2024?
During 2025-2034, the Asia Pacific is anticipated to expand at a rapid CAGR in the exosome research market as many emerging Asian economies, including Indonesia, India, and the Philippines, are expected to experience strong growth driven by vigorous domestic investment. The region cooperatively outperformed global growth prospects and cemented its role as a leading contributor to the biosphere economy. Growing spend in research and technology, for instance, South Korea’s Korea Drug Development Fund (KDDF) has committed US$1.6 billion to over 1,200 projects by 2030
Immediate Delivery Available | Buy This Premium Research (Global Deep Dive USD 3800) https://www.novaoneadvisor.com/report/checkout/9263
Segmental Insights
By product type analysis
Which Product Type Led the Exosome Research Market in 2024?
The reagents and kits segment accounted for the dominating share of the market in 2024, as profitable exome capture kits offer a significantly effective way to sequence a select region of the genome at very high precision. It offers scientists the capabilities to use sequencing and analysis resources more predominantly by focusing on the most relevant share of the genome.
Whereas the RNA/DNA extraction kits segment is predicted to register rapid expansion in the coming era, as DNA and RNA support to facilitate tailor-made health management decisions in medical practice most inclusively. These kits are usually designed to extract RNA from specific sample types (such as blood, tissue, or plant) and are further categorized. These kits are designed to effectively eliminate contaminants such as proteins, lipids, salts, and PCR inhibitors.
By application analysis
How did the Cancer Research Segment Dominate the Market in 2024?
In 2024, the cancer research segment captured the biggest share of the exosome research market as cancer exome sequencing enables scientists to assess only coding regions, which often contain alterations that affect tumor development. Using NGS technology gives investigators more inclusive data and more detection power than achieved through PCR.
Although the drug delivery systems segment will expand fastest during 2025-2034, as exosomes show exclusive biocompatibility, low immunogenicity, and lower toxicity. Furthermore, exosomes are designed and tailored to enhance targeting effectiveness, cargo loading capacity, and stability, creating the way for targeted medicine and accurate therapy. An exosome-based delivery system has specifically advantages, like safety, specificity, and stability.
By workflow analysis
Which Type of Workflow Dominated the Exosome Research Market in 2024?
The isolation segment captured the largest share of the market in 2024 as appropriate isolation eliminates impurities such as RNA, proteins, lipids, and other cellular debris that interfere with subsequent enzymatic reactions. This is significant for generating clean and reliable sequencing information. Effective isolation protocols, particularly those involving appropriate sample handling and storage, support to prevent the degradation of DNA by nucleases.
On the other hand, the microfluidics-based isolation segment will expand rapidly as microfluidic-based exosome separation has been reported to be rapid and more efficient than conventional techniques because of the various forces generated by electric and acoustic fields and hydrodynamic forces. Different microfluidic devices that utilize dielectrophoretic (DEP) forces have been industrialized to capture and isolate exosomes.
By application analysis
Why did the Vaccine Manufacturing Segment Lead the Market in 2024?
The vaccine manufacturing segment accounted for a dominant share of the Exosome Research Market in 2024, as the broader acceptance of microcarriers provides a high-surface-area platform for anchoring-driven cells, enabling greater cell densities and volumes of vaccine to be manufactured in a limited time compared to conventional strategies. The exploration of SUBs is enabling many benefits for vaccine manufacturing with the lower risk of contamination, omission of sterilization and cleaning steps, and radically lowering the turnaround time in the production batches.
However, the cell therapy & regenerative medicine segment is estimated to witness rapid expansion as scientists are actively involved in the advancement of stimuli-responsive microcarriers, such as magnetic or electroactive, that can be accomplished externally, along with the application of xeno-free and biodegradable materials for prolonged compatibility and safety. Furthermore, the sector is leveraging the mixture of microcarriers into 3D bioprinting and injectable formulations for possible delivery.
By end-user analysis
How did the Academic and Research Institutes Segment Dominate the Market in 2024?
The academic & research institutes segment held the biggest share of the exosome research market in 2024, as academic centers are instrumental in the discovery of new disease-causing variants and genes, particularly for rare Mendelian disorders and multifaceted traits. Academic institutions drive large-scale, population-based research that generates massive amounts of information.
On the other hand, the pharmaceutical & biotechnology companies segment will expand fastest as exosome research enables the identification of disease-causing mutations, drives the discovery of novel therapeutic targets, and offers the basis for targeted treatment plans. Additionally, it aids in the advancement of more efficient drugs with lower adverse effects.
Top Companies in the Exosome Research Market
- Thermo Fisher Scientific
- Bio-Techne Corporation
- System Biosciences (SBI)
- QIAGEN
- NanoView Biosciences
- Miltenyi Biotec
- Danaher Corporation
- Exosome Diagnostics
- Lonza
- Norgen Biotek Corp
- Malvern Panalytical
- NanoFCM
- Creative Biolabs
- AMS Biotechnology
- Evox Therapeutics
- HansaBioMed Life Sciences
- Diagenode
- Exosomics
- Aruna Bio
- Labcorp Drug Development
What are the Recent Developments in the Exosome Research Market?
- In October 2025, as per DelveInsight’s assessment, globally, the Exosomes pipeline constitutes 80+ key companies continuously working towards developing 100+ Exosomes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
- In August 2025, mdxhealth signed a definitive agreement to acquire Exosome Diagnostics, Inc. from Bio-Techne, including the ExoDx Prostate (EPI) test, a CLIA-certified clinical laboratory, and related assets. Total consideration for the acquisition is $15 million, with $5 million in stock paid at closing and $2.5 million to be paid annually over the following 4 years, with 50% in cash and 50% in cash or stock at MDXHealth’s discretion.
More Insights in Nova One Advisor:
- Chemiluminescence Immunoassay Market – The global chemiluminescence immunoassay market size was valued at USD 16.65 billion in 2024 and is anticipated to reach around USD 33.09 billion by 2034, growing at a CAGR of 7.11% from 2025 to 2034.
- Healthcare Business Intelligence Market – The global healthcare business intelligence market size was estimated at USD 10.55 billion in 2024 and is expected to reach USD 37.56 billion in 2034, expanding at a CAGR of 13.54% during the forecast period of 2025 to 2034.
- Plasma Fractionation Market – The plasma fractionation market size was exhibited at USD 35.25 billion in 2024 and is projected to hit around USD 80.44 billion by 2034, growing at a CAGR of 8.6% during the forecast period 2025 to 2034.
- Middle East Patient Engagement Solutions Market – The Middle East patient engagement solutions market size was estimated at USD 690.35 million in 2024 and is expected to reach USD 5,684.39 million in 2034, expanding at a CAGR of 23.47% during the forecast period of 2025 and 2034.
- U.S. Credentialing Software And Services In Healthcare Market– The U.S. credentialing software and services in healthcare market was valued at USD 268.35 billion in 2024 and is projected to hit around USD 526.41 billion by 2034, growing at a CAGR of 6.97% during the forecast period 2025 to 2034.
- AI in Clinical Trials Market – The global AI in clinical trials market size was valued at USD 2.85 billion in 2024 and is anticipated to reach around USD 31.28 billion by 2034, growing at a CAGR of 27.07% from 2025 to 2034.
- Middle East Digital Health Market – The Middle East digital health market was valued at USD 11.45 billion in 2024 and is projected to hit around USD 89.87 billion by 2034, growing at a CAGR of 22.88% during the forecast period 2025 to 2034.
- Biopharmaceutical Third-party Logistics Market – The global biopharmaceutical third-party logistics size was exhibited at USD 143.65 billion in 2024 and is projected to hit around USD 271.94 billion by 2034, growing at a CAGR of 6.59% during the forecast period of 2025 to 2034.
- Women’s Health App Market – The women’s health app market size was exhibited at USD 4.95 billion in 2024 and is projected to hit around USD 25.45 billion by 2034, growing at a CAGR of 17.79% during the forecast period 2025 to 2034.
- Remote Healthcare Market – The global Remote Healthcare market gathered revenue around USD 83.35 Billion in 2024 and market is set to grow USD 584.34 Billion by the end of 2034 and is estimated to expand at a modest CAGR of 21.5% during the prediction period 2025 to 2034.
- Patient Positioning Systems Market – The global Patient Positioning Systems market gathered revenue around USD 2.15 Billion in 2024 and market is set to grow USD 3.19 Billion by the end of 2034 and is estimated to expand at a modest CAGR of 4.03% during the prediction period 2025 to 2034.
- Cell Expansion Market – The global cell expansion market size is calculated at USD 22.97 billion in 2024, grows to USD 25.93 billion in 2025, and is projected to reach around USD 77.08 billion by 2034, registering a CAGR of 12.87% over the forecast period of 2025 to 2034.
Exosome research Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. For this study, Nova One Advisor has segmented the global exosome research Market
Segments Covered in the Report
By Product Type
- Instruments
- Ultracentrifuges
- Nanoparticle Tracking Analyzers
- Flow Cytometers
- Others
- Reagents & Kits
- Isolation Kits
- Labeling & Detection Kits
- RNA/DNA Extraction Kits
- Antibodies
- Others
- Software Tools & Platforms
- Services
- Custom Isolation Services
- Exosome Profiling Services
- Exosome Engineering Services
- Others
By Application
- Cancer Research
- Neurodegenerative Disease Research
- Cardiovascular Disease Research
- Infectious Disease Research
- Drug Delivery Systems
- Biomarker Discovery
- Others
By Workflow
- Isolation
- Ultracentrifugation
- Size-exclusion Chromatography
- Immunoaffinity Capture
- Microfluidics-based Isolation
- Precipitation
- Others
- Characterization
- NTA (Nanoparticle Tracking Analysis)
- Western Blotting
- Electron Microscopy
- DLS (Dynamic Light Scattering)
- ELISA
- Others
- Profiling
- Proteomics
- Genomics
- Lipidomics
- Others
By End User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Clinical Laboratories
- Hospitals
- CROs & CDMOs
- Others
By Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Immediate Delivery Available | Buy This Premium Research Report (Global Deep Dive USD 3800) https://www.novaoneadvisor.com/report/checkout/9263
About-Us
Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.
Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.
Our Trusted Data Partners
Towards Chemical and Materials | Precedence Research | Statifacts | Towards Packaging | Towards Healthcare | Towards Food and Beverages | Towards Automotive | Towards Consumer Goods | Nova One Advisor | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics | Towards Chem and Material
Web: https://www.novaoneadvisor.com/
Contact Us
USA: +1 804 420 9370
Email: sales@novaoneadvisor.com
For Latest Update Follow Us: LinkedIn
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.